Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Long

Showing results (441-450 of 703) with videos related to

Pageof 71
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 13, 2025
Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year updateEvan J Lipson, F Stephen Hodi, Hussein Tawbi, et al.
Cancer Discovery|November 23, 2013
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapyHubing Shi, Willy Hugo, Xiangju Kong, et al.
Future Oncology (London, England)|May 26, 2025
A plain language summary of POLARIS: a study to look at different doses of encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasisAlexander M Menzies, Georgina V Long, Amiee Kohn, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2021
Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapyAdriana Hepner, Victoria G Atkinson, James Larkin, et al.
NPJ Precision Oncology|January 22, 2026
Prospective tumour mutation burden and neoantigen profiling predicts immunotherapy response in metastatic melanomaYizhe Mao, Tuba N Gide, Nigel G Maher, et al.
Neuro-Oncology Advances|May 10, 2024
POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with <i>BRAF</i> V600-mutant melanoma with brain metastasisAlexander M Menzies, Georgina V Long, Amiee Kohn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2024
Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanomaA M Menzies, S N Lo, R P M Saw, et al.
Nature Medicine|November 4, 2023
Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trialJohn M Kirkwood, Michele Del Vecchio, Jeffrey Weber, et al.
JAMA Oncology|March 25, 2021
Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected MelanomaJ Randall Patrinely, Rebecca Johnson, Aleigha R Lawless, et al.
Oncoimmunology|February 25, 2021
A multicenter characterization of hepatitis associated with immune checkpoint inhibitorsJ Randall Patrinely, Ben McGuigan, Sunandana Chandra, et al.
Pageof 71

Showing results (441-450 of 703) with videos related to

Sort By:
Pageof 71
European Journal of Cancer (Oxford, England : 1990)|June 13, 2025
Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year updateEvan J Lipson, F Stephen Hodi, Hussein Tawbi, et al.
Cancer Discovery|November 23, 2013
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapyHubing Shi, Willy Hugo, Xiangju Kong, et al.
Future Oncology (London, England)|May 26, 2025
A plain language summary of POLARIS: a study to look at different doses of encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasisAlexander M Menzies, Georgina V Long, Amiee Kohn, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2021
Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapyAdriana Hepner, Victoria G Atkinson, James Larkin, et al.
NPJ Precision Oncology|January 22, 2026
Prospective tumour mutation burden and neoantigen profiling predicts immunotherapy response in metastatic melanomaYizhe Mao, Tuba N Gide, Nigel G Maher, et al.
Neuro-Oncology Advances|May 10, 2024
POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with <i>BRAF</i> V600-mutant melanoma with brain metastasisAlexander M Menzies, Georgina V Long, Amiee Kohn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2024
Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanomaA M Menzies, S N Lo, R P M Saw, et al.
Nature Medicine|November 4, 2023
Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trialJohn M Kirkwood, Michele Del Vecchio, Jeffrey Weber, et al.
JAMA Oncology|March 25, 2021
Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected MelanomaJ Randall Patrinely, Rebecca Johnson, Aleigha R Lawless, et al.
Oncoimmunology|February 25, 2021
A multicenter characterization of hepatitis associated with immune checkpoint inhibitorsJ Randall Patrinely, Ben McGuigan, Sunandana Chandra, et al.
Pageof 71